News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

INNOVIVE Pharmaceuticals Presents Preliminary Data at American Society of Hematology Showing INNO-305 Elicits Immune Response in Patients with Myeloid and Thoracic Neoplasms



12/9/2007 11:55:41 PM

ATLANTA--(BUSINESS WIRE)--INNOVIVE Pharmaceuticals, Inc. (OTCBB:IVPH) today presented results from a pilot study examining INNO-305, a Wilms Tumor Protein (WT1) heteroclitic peptide immunotherapeutic vaccine, in patients with myeloid and thoracic neoplasms. Preliminary data from the pilot study suggests repeat administration with INNO-305 is well tolerated and immune response can be elicited following three vaccinations. The data were presented at the 49th American Society of Hematology (ASH) Annual Meeting in Atlanta.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES